Literature DB >> 21410696

Moving towards meaningful measurement: Rasch analysis of the North Star Ambulatory Assessment in Duchenne muscular dystrophy.

Anna Mayhew1, Stefan Cano, Elaine Scott, Michelle Eagle, Kate Bushby, Francesco Muntoni.   

Abstract

AIM: Reliable measurement of disease progression and the effect of therapeutic interventions in Duchenne muscular dystrophy (DMD) require clinically meaningful and scientifically sound rating scales. Therefore, we need robust evidence to support such tools. The North Star Ambulatory Assessment (NSAA) is a promising, clinician-rated scale with potential uses spanning clinical practice and clinical trials. In this study, we used Rasch analysis to test its suitability in these roles as a measurement instrument.
METHOD: NSAA data from 191 ambulant boys (mean age at assessment 7 y 8 mo, SD 2 y 4 mo; range 3 y 6 mo-15 y 5 mo) with a confirmed diagnosis of DMD were examined for psychometric properties including clinical meaning, targeting, response categories, model fit, reliability, dependency, stability, and raw to interval-level measurement. All analyses were performed using the Rasch Unidimensional Measurement Model.
RESULTS: Overall, Rasch analysis supported the NSAA as being a reliable (high Person Separation Index of 0.91) and valid (good targeting, little misfit, no reversed thresholds) measure of ambulatory function in DMD. One item displayed misfit (lifts head, fit residual 6.9) and there was evidence for some local dependency (stand on right/left leg, climb and descend box step right/left leg, and hop on right/left leg, residual correlations >0.40), which we provide potential solutions for in future use of the NSAA. Importantly, our findings supported good clinical validity in that the hierarchy of items within the scale produced by the analyses was supported by clinical opinion, thus increasing the clinical interpretability of scale scores.
INTERPRETATION: In general, Rasch analysis supported the NSAA as a psychometrically robust scale for use in DMD clinical research and trials. This study also demonstrates how Rasch analysis is a useful instrument to detect and understand the key measurement issues of rating scales. © The Authors. Developmental Medicine & Child Neurology
© 2011 Mac Keith Press.

Entities:  

Mesh:

Year:  2011        PMID: 21410696     DOI: 10.1111/j.1469-8749.2011.03939.x

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  36 in total

1.  Rasch analysis of clinical outcome measures in spinal muscular atrophy.

Authors:  Stefan J Cano; Anna Mayhew; Allan M Glanzman; Kristin J Krosschell; Kathryn J Swoboda; Marion Main; Birgit F Steffensen; Carole Bérard; Françoise Girardot; Christine A M Payan; Eugenio Mercuri; Elena Mazzone; Bakri Elsheikh; Julaine Florence; Linda S Hynan; Susan T Iannaccone; Leslie L Nelson; Shree Pandya; Michael Rose; Charles Scott; Reza Sadjadi; Mackensie A Yore; Cynthia Joyce; John T Kissel
Journal:  Muscle Nerve       Date:  2013-07-26       Impact factor: 3.217

Review 2.  Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management.

Authors:  David J Birnkrant; Katharine Bushby; Carla M Bann; Susan D Apkon; Angela Blackwell; David Brumbaugh; Laura E Case; Paula R Clemens; Stasia Hadjiyannakis; Shree Pandya; Natalie Street; Jean Tomezsko; Kathryn R Wagner; Leanne M Ward; David R Weber
Journal:  Lancet Neurol       Date:  2018-02-03       Impact factor: 44.182

3.  Use of Rasch Analysis to Evaluate and Refine the Community Balance and Mobility Scale for Use in Ambulatory Community-Dwelling Adults Following Stroke.

Authors:  Kimberly J Miller; Courtney L Pollock; Brenda Brouwer; S Jayne Garland
Journal:  Phys Ther       Date:  2016-04-14

Review 4.  The role of the neuromuscular medicine and physiatry specialists in the multidisciplinary management of neuromuscular disease.

Authors:  Craig M McDonald; William M Fowler
Journal:  Phys Med Rehabil Clin N Am       Date:  2012-08       Impact factor: 1.784

5.  Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings.

Authors:  Kate Bushby; Edward Connor
Journal:  Clin Investig (Lond)       Date:  2011-09

6.  Validation of the Charcot-Marie-Tooth disease pediatric scale as an outcome measure of disability.

Authors:  Joshua Burns; Robert Ouvrier; Tim Estilow; Rosemary Shy; Matilde Laurá; Julie F Pallant; Monkol Lek; Francesco Muntoni; Mary M Reilly; Davide Pareyson; Gyula Acsadi; Michael E Shy; Richard S Finkel
Journal:  Ann Neurol       Date:  2012-05       Impact factor: 10.422

7.  The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used.

Authors:  Craig M McDonald; Erik K Henricson; R Ted Abresch; Jay J Han; Diana M Escolar; Julaine M Florence; Tina Duong; Adrienne Arrieta; Paula R Clemens; Eric P Hoffman; Avital Cnaan
Journal:  Muscle Nerve       Date:  2013-05-16       Impact factor: 3.217

Review 8.  Ongoing therapeutic trials and outcome measures for Duchenne muscular dystrophy.

Authors:  Alessandra Govoni; Francesca Magri; Simona Brajkovic; Chiara Zanetta; Irene Faravelli; Stefania Corti; Nereo Bresolin; Giacomo P Comi
Journal:  Cell Mol Life Sci       Date:  2013-06-18       Impact factor: 9.261

9.  Rasch analysis of the motor function measure in patients with congenital muscle dystrophy and congenital myopathy.

Authors:  Carole Vuillerot; Pascal Rippert; Virginie Kinet; Anne Renders; Minal Jain; Melissa Waite; Allan M Glanzman; Francoise Girardot; Dalil Hamroun; Jean Iwaz; René Ecochard; Susana Quijano-Roy; Carole Bérard; Isabelle Poirot; Carsten G Bönnemann
Journal:  Arch Phys Med Rehabil       Date:  2014-06-25       Impact factor: 3.966

10.  The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures.

Authors:  Erik K Henricson; R Ted Abresch; Avital Cnaan; Fengming Hu; Tina Duong; Adrienne Arrieta; Jay Han; Diana M Escolar; Julaine M Florence; Paula R Clemens; Eric P Hoffman; Craig M McDonald
Journal:  Muscle Nerve       Date:  2013-05-06       Impact factor: 3.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.